Systemic Sclerosis

Prof. Chit Soe
Professor and Head
Rheumatology Department
University of Medicine 1

ARD Online First, published on April 25, 2017 as 10.1136/annrheumdis-2016-209909

Recommendation

Update of EULAR recommendations for the treatment of systemic sclerosis

Otylia Kowal-Bielecka,[1] Jaap Fransen,[2] Jerome Avouac,[3] Mike Becker,[4,5] Agnieszka Kulak,[1] Yannick Allanore,[3] Oliver Distler,[5] Philip Clements,[6] Maurizio Cutolo,[7] Laszlo Czirjak,[8] Nemanja Damjanov,[9] Francesco del Galdo,[10]

Ontario Rheumatology Association

ACR – EULAR Classification Criteria for Systemic Sclerosis

- Sindhu Johnson MD PhD

May 25, 2013

ACR Preliminary Classification Criteria for Systemic Sclerosis

- **Major criterion or 2 minor criteria**

Major criterion

* Proximal scleroderma

Minor criteria

* Sclerodactyly
* Digital pitting or scars or loss of substance from finger pad
* Bibasilar pulmonary fibrosis

Arthritis Rheum 1980; 23:581-90

ACR Preliminary Classification Criteria for Systemic Sclerosis

- **1 major criterion or ≥ 2 minor criteria**

Sensitivity 97% of definite SSc cases

Specificity 98% the comparison patients

Arthritis Rheum 1980; 23:581-90

Classification schemes – Overview



Ontario Rheumatology Association

1. These criteria are applicable to any patient considered for inclusion in a SSc study.
2. These criteria are **not applicable** to:

a) Patients having a SSc-like disorder better explaining their manifestations, such as: nephrogenic sclerosing fibrosis, generalized morphea, eosinophilic fasciitis, scleredema diabeticorum, scleromyxedema, erythromyalgia, porphyria, lichen sclerosis, graft versus host disease, and diabetic cheiropathy. b) Patients with '***Skin thickening sparing the fingers'***,

Items	**Sub-items**	**Weight / Score**
Skin thickening of the fingers of both hands extending proximal to the metacarpophalangeal joints *(sufficient criterion)*		9
Skin thickening of the fingers^ *(only count the highest score)*	Puffy fingers	2
	Sclerodactyly of the fingers (distal to MCP but proximal to the PIPs)	4
Finger tip lesions^ *(only count the highest score)*	Digital Tip Ulcers	2
	Finger Tip Pitting Scars	3
Telangiectasia		2
Abnormal nailfold capillaries		2
Pulmonary arterial hypertension and/or Interstitial lung Disease* (*Maximum score is 2)	PAH ILD	2
Raynaud's phenomenon		3
Scleroderma related antibodies** (any of anti-centromere, anti-topoisomerasel [anti-Scl 70], anti-RNA polymerase III) (**Maximum score is 3)	Anti-centromere Anti-topoisomerasel Anti-RNA polymerase III	3
	TOTAL SCORE^:	

Patients having a total score of <u>9 or more</u> are being classified as having definite systemic sclerosis. ^ Add the maximum weight (score) in each category to calculate the total score.


© 2009 American College of Rheumatology


© 2008 American College of Rheumatology



Nail fold capillary loop



- Normal- hairpin like
- faint
- subcuticular cap h’age
- dilated and bizzare loops

Raynaud





Telangiectasia

ILD on HRCT



ANA (nucleolar)



	Derivation sample (N=200)		Validation sample (N=405)		Validation sample ≤ 3 years disease duration (N=100)	
	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
1980 ARA SSc Criteria	0.80 (0.72, 0.87)	0.77 (0.68, 0.84)	**0.75** (0.70, 0.80)	**0.72** (0.64, 0.79)	0.75 (0.70, 0.80)	0.72 (0.63, 0.79)
2001 LeRoy and Medsger criteria	0.76 (0.68, 0.84)	0.69 (0.68, 0.84)	0.75 (0.70, 0.80)	0.78 (0.70, 0.85)	0.80 (0.69, 0.88)	0.76 (0.53, 0.92)
2013 ACR-EULAR SSc Classification Criteria	0.95 (0.90, 0.98)	0.93 (0.86, 0.97)	**0.91** (0.87, 0.94)	**0.92** (0.86, 0.96)	0.91 (0.83, 0.96)	0.90 (0.70, 0.99)

EPIDEMIOLOGY

- Age of Onset - 30 to 50 years.
- Rare in children.
- Sex - Female:male ratio 3:1.
- Occur world-wide with no racial differences
- Etiology - Unknown.

YSH Admission 2016-2017

Year	SLE	RA	PSS	MCTD	Overlaps	Polymyositis	Takayasu	others	Total
2017	1938	119	355	130	60	89	71	238	3004
2016	1949	136	383	77	29	21	66	228	2884

Pathogenesis

- 3 processes : d/m to v/s endothelium

  immunologic and infla-mmatory activation

  dysregulated extracellular matrix metabolism
- autoimmune Abs directed at cellular targets as clinically valuable prognostic indicators
- ACA and Scl-70 – 50 – 85% prevalence and 90% specificity for CREST $

- Mechanism of endothelial damage is unclear
- Cytotoxic autoantibodies is one mechanism
- Biochemical changes include decreased vWF,F VIII&Weibel-Palade bodies
- Decrease adenosine

  uptake&membrame blebbing

  Release of proinflammatory cytokines,prostaglandins,NO &endothelin-1 affect v/s beds

- Platelet aggregation & activation occur,lead to release of PDGF, potent mitogen for fibroblast & smooth m/s→ thickening of v/s wall
- Role of immune response involves CD4+ T cells, plasma cell,histiocytes→t/s fibrosis
- Elevated level of IL4,IL-10&IL-13→TH2 response
- IL-4→collagen upregulation&counter byIFN-r
- IFN-r is produced byTH1→unchange in SSc→increase production of I,II,VI collagen

Microtubules pathology in PSS



Autoantibody Associations with Scleroderma

Antibody	Prevalence (%)	Clinical associations
Anti-topoisomerase1 (Scl-70)	20 – 40	Diffuse skin disease ,Interstitial lung disease Increased mortality, Cardiac disease
Anti-centromere	20 – 40	CREST syndrome , Digital loss ,Pulmonary hypertension ,Primary biliary cirrhosis
Nucleolar antibodies		
RNA Polymerases	4 – 20	Renal crisis, Cardiac disease ,Diffuse skin disease, Tendon friction rubs, incresed mortality
U3snRNP (fibrillarin)	8	African-American males, Diffuse skin disease, Pulmonary disease
Th	5	Limited skin disease
Nor-90	Rare	Unknown
Pm-Scl	1	Myositis
U1snRNP	5	Mixed connective tissue disease



Fig. 35.24 **Total skin score.** Semiquantitative estimates by clinical palpation of

Diagnostic Features of PSS (CS 2003-TSGH n=20)

Sclerodactyly	+	14	77.8%
	-	4	22.2%
Pitting Pulp Scar	+	10	55.6%
	-	8	44.4%
Proximal Scleroderma	+	11	61.1%
	-	7	38.9%
Scleroderma Face	+	16	88.9%
	-	2	11.1%

CREST

Raynaud's Phenomenon	+	14	77.8%
	-	4	22.2%
Dysphagia	+	9	50%
	-	9	50%
Sclerodactyly	+	14	77.8%
	-	4	22.2%
Telengiectasia	+	7	38.9%
	-	11	61.1%


Calcinosis





Other Features

Vasculitis	+	6	33.3%
	-	12	66.7%
Malar Rash	+	7	38.9%
	-	11	61.1%
Oral Ulcers	+	1	5.6%
	-	17	94.4%
Photosensitivity	+	12	66.7%
	-	6	33.3%
Proximal Myopathy	+	11	61.1%
	-	7	38.9%
Renal Involvement	+	6	33.3%
	-	12	66.7%

Telangiectasias of the fingers



Finger tip ulceration



Digital loss in patient with limited scleroderma and anticentromere antibodies





Gangrene and auto-amputation

Large bowel involvement: Barium study showing wide-mouthed colonic diverticula





Coup de sabre. Linear, atrophic depression involving the forehead.

PSS patients



3 finger test for fishmouth





Quality of Life

FHS	1	5	25%
	2	12	60%
	3	2	10%
	4	1	5%
HAQ	0-1	10	52.6%
	1-2	6	31.6%
	2-3	3	15.8%
Mqol	0-1	7	41.2%
	1-2	4	23.5%
	2-3	3	17.6%
	3-4	3	17.6%
VAPS	0-5	9	50%
	5-10	9	50%
OHS	0-5	7	53.8%
	5-10	6	46.2%

Quality of life

- Functional health status (FHS) I was applicable to 25%,
- FHS II to 60%,
- FHS III to 10% and
- FHS 4 to only 5%.
- Majority has HAQ score of <1 (52%) and
- Mqol score of <1 (41%)

Fish mouth and Beaking Nose





Digital pitting scar





Terminal resorption





Treatment

Table 1 The updated EULAR recommendations for treatment of systemic sclerosis, according to the organ involvement, includi recommendations and the results of internal evaluation within the task force group

Organ involvement	Recommendation	Level of evidence	Strength of recommendation
I. SSc-RP	Dihydropiridine-type calcium antagonists, usually oral nifedipine, should be considered for first-line therapy for SSc-RP. PDE-5 inhibitors should also be considered in treatment of SSc-RP.	1A	A
	Intravenous iloprost should be considered for severe SSc-RP. Experts recommend that intravenous iloprost should be used for treatment of SSc-RP attacks after oral therapy.	1A	A
	Fluoxetine might be considered in treatment of SSc-RP attacks.	3	C
II. Digital ulcers in patients with SSc	Intravenous iloprost should be considered in the treatment of digital ulcers in patients with SSc.	1B	A
	PDE-5 inhibitors should be considered in the treatment of digital ulcers in patients with SSc.	1A	A
	Bosentan should be considered for reduction of the number of new digital ulcers in SSc, especially in patients with multiple digital ulcers despite use of calcium channel blockers, PDE-5 inhibitors or iloprost therapy.	1B	A

Lung fibrosis (HRCT)



III. SSc-PAH	ERA, PDE-5 inhibitors or riociguat should be considered to treat SSc-related PAH.	1B	B
	Intravenous epoprostenol should be considered for the treatment of patients with severe SSc-PAH (class III and IV).	1B	A
	Prostacyclin analogues should be considered for the treatment of patients with SSc-PAH.	1B	B
IV. Skin and lung disease	Methotrexate may be considered for treatment of skin manifestations of early diffuse SSc.	1B	A
	In view of the results from two high-quality RCTs and despite its known toxicity, cyclophosphamide should be considered for treatment of SSc-ILD, in particular for patients with SSc with progressive ILD.	1B	A
	HSCT should be considered for treatment of selected patients with rapidly progressive SSc at risk of organ failure. In view of the high risk of treatment-related side effects and of early treatment-related mortality, careful selection of patients with SSc for this kind of treatment and the experience of the medical team are of key importance.	1B	A

V. SRC	Experts recommend immediate use of ACE inhibitors in the treatment of SRC.	3	C
	Blood pressure and renal function should be carefully monitored in patients with SSc treated with glucocorticoids.	3	C
VI. SSc-related gastrointestinal disease	PPI should be used for the treatment of SSc-related gastro-oesophageal reflux and prevention of oesophageal ulcers and strictures.	1A	C
	Prokinetic drugs should be used for the management of SSc-related symptomatic motility disturbances (dysphagia, GERD, early satiety, bloating, pseudo-obstruction, etc).	3	C
	Intermittent or rotating antibiotics should be used to treat symptomatic small intestine bacterial overgrowth in patients with SSc.	3	D

Cleve Clin J Med. 2003 Nov;70(11):954, 956, 958

Trial drugs

- including bosentan, an endothelin receptor antagonist,
- and epoprostenol, a prostacyclin, both of which target vasoconstriction.

Treatment

Holostic Solution

Social & Family Planning	• Counseling with partner • Rehabilitation
Prevention CVD & infection	• CVD risk stratification • Immunization
Complication & Co-morbidity	• Vasculitic ulcers • Osteoporosis • TB
Extra-articular	• Lung, GI, Renal
Skin & Arthritis	• NSAID, Steroid, DMARD • Biologics

Poor prognosis

- Older age
- Long disease duration >5 yr (Non-Raynaud)
- Diffuse skin disease
- Proteinuria
- High ESR
- Low TLCO
- Reduced FVC, <70%
- Pulmonary hypertension >75mmHg

Take Home

- PSS is not an uncommon disease in Rheumatology practice
- If diagnosed early and treat timely, the progress can be stopped and maintain quality of life
- Raynaud's phenomenon or abnormal tightening of skin lasting more than 3 months should be referred to specialists for thorough investigation


Thank You
PING